Evaxion Biotech's lung cancer candidate ready for clinic

The next candidate developed by Evaxion Biotech is ready to enter the clinical phase. This candidate is a potential treatment for non-small cell lung cancer called EVX-03, the biotech firm reveals.

Evaxion Biotech CEO Lars Staal Wegner | Photo: Evaxion Biotech / PR

Biotech firm Evaxion Biotech has decided to take its EVX-03 candidate, a potential treatment for non-small cell lung cancer (NSCLC), into the clinical phase.

The announcement made on Thursday also states that the candidate will target patients with advanced cancer.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs